200 related articles for article (PubMed ID: 31941718)
41. Recombinant high density lipoprotein reconstituted with apolipoprotein AI cysteine mutants as delivery vehicles for 10-hydroxycamptothecin.
Zhang X; Chen B
Cancer Lett; 2010 Dec; 298(1):26-33. PubMed ID: 20579804
[TBL] [Abstract][Full Text] [Related]
42. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase.
Blatter MC; James RW; Messmer S; Barja F; Pometta D
Eur J Biochem; 1993 Feb; 211(3):871-9. PubMed ID: 8382160
[TBL] [Abstract][Full Text] [Related]
43. High-Density Lipoprotein-Targeted Therapy and Apolipoprotein A-I Mimetic Peptides.
Uehara Y; Chiesa G; Saku K
Circ J; 2015; 79(12):2523-8. PubMed ID: 26548857
[TBL] [Abstract][Full Text] [Related]
44. Effects of protein oxidation on the structure and stability of model discoidal high-density lipoproteins.
Jayaraman S; Gantz DL; Gursky O
Biochemistry; 2008 Mar; 47(12):3875-82. PubMed ID: 18302337
[TBL] [Abstract][Full Text] [Related]
45. Apolipoprotein A-I configuration and cell cholesterol efflux activity of discoidal lipoproteins depend on the reconstitution process.
Cuellar LÁ; Prieto ED; Cabaleiro LV; Garda HA
Biochim Biophys Acta; 2014 Jan; 1841(1):180-9. PubMed ID: 24201377
[TBL] [Abstract][Full Text] [Related]
46. Single step reconstitution of multifunctional high-density lipoprotein-derived nanomaterials using microfluidics.
Kim Y; Fay F; Cormode DP; Sanchez-Gaytan BL; Tang J; Hennessy EJ; Ma M; Moore K; Farokhzad OC; Fisher EA; Mulder WJ; Langer R; Fayad ZA
ACS Nano; 2013 Nov; 7(11):9975-83. PubMed ID: 24079940
[TBL] [Abstract][Full Text] [Related]
47. Apolipoprotein A-II is a key regulatory factor of HDL metabolism as appears from studies with transgenic animals and clinical outcomes.
Maïga SF; Kalopissis AD; Chabert M
Biochimie; 2014 Jan; 96():56-66. PubMed ID: 24012775
[TBL] [Abstract][Full Text] [Related]
48. [Recent development of natural and reconstituted lipoprotein based nano drug delivery vehicles].
Xu Y; Jin XF; Ping QN; Liu HF; Chen M; Xu XM
Yao Xue Xue Bao; 2014 Jan; 49(1):23-9. PubMed ID: 24783501
[TBL] [Abstract][Full Text] [Related]
49. Phospholipid Component Defines Pharmacokinetic and Pharmacodynamic Properties of Synthetic High-Density Lipoproteins.
Fawaz MV; Kim SY; Li D; Ming R; Xia Z; Olsen K; Pogozheva ID; Tesmer JJG; Schwendeman A
J Pharmacol Exp Ther; 2020 Feb; 372(2):193-204. PubMed ID: 31776208
[TBL] [Abstract][Full Text] [Related]
50. 5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice.
Amar MJ; D'Souza W; Turner S; Demosky S; Sviridov D; Stonik J; Luchoomun J; Voogt J; Hellerstein M; Sviridov D; Remaley AT
J Pharmacol Exp Ther; 2010 Aug; 334(2):634-41. PubMed ID: 20484557
[TBL] [Abstract][Full Text] [Related]
51. Role of individual amino acids of apolipoprotein A-I in the activation of lecithin:cholesterol acyltransferase and in HDL rearrangements.
Cho KH; Durbin DM; Jonas A
J Lipid Res; 2001 Mar; 42(3):379-89. PubMed ID: 11254750
[TBL] [Abstract][Full Text] [Related]
52. HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting.
Zhang Z; Chen J; Ding L; Jin H; Lovell JF; Corbin IR; Cao W; Lo PC; Yang M; Tsao MS; Luo Q; Zheng G
Small; 2010 Feb; 6(3):430-7. PubMed ID: 19957284
[TBL] [Abstract][Full Text] [Related]
53. Indium-111 labeling of high-density lipoprotein-mimicking phospholipid-styrene maleic acid copolymer complexes and its biodistribution in mice.
Tanaka M; Hosotani A; Mukai T
J Labelled Comp Radiopharm; 2018 Sep; 61(11):857-863. PubMed ID: 29972867
[TBL] [Abstract][Full Text] [Related]
54. Reconstituted HDL as a therapeutic delivery device.
Fox CA; Moschetti A; Ryan RO
Biochim Biophys Acta Mol Cell Biol Lipids; 2021 Nov; 1866(11):159025. PubMed ID: 34375767
[TBL] [Abstract][Full Text] [Related]
55. Nanoparticle Targeting and Cholesterol Flux Through Scavenger Receptor Type B-1 Inhibits Cellular Exosome Uptake.
Plebanek MP; Mutharasan RK; Volpert O; Matov A; Gatlin JC; Thaxton CS
Sci Rep; 2015 Oct; 5():15724. PubMed ID: 26511855
[TBL] [Abstract][Full Text] [Related]
56. Recent advances on the antiatherogenic effects of HDL-derived proteins and mimetic peptides.
Petraki MP; Mantani PT; Tselepis AD
Curr Pharm Des; 2009; 15(27):3146-66. PubMed ID: 19754388
[TBL] [Abstract][Full Text] [Related]
57. Mimetic sHDL nanoparticles: A novel drug-delivery strategy to target triple-negative breast cancer.
Wang T; Subramanian C; Yu M; White PT; Kuai R; Sanchez J; Moon JJ; Timmermann BN; Schwendeman A; Cohen MS
Surgery; 2019 Dec; 166(6):1168-1175. PubMed ID: 31371177
[TBL] [Abstract][Full Text] [Related]
58. A retained secretory signal peptide mediates high density lipoprotein (HDL) assembly and function of haptoglobin-related protein.
Harrington JM; Nishanova T; Pena SR; Hess M; Scelsi CL; Widener J; Hajduk SL
J Biol Chem; 2014 Sep; 289(36):24811-20. PubMed ID: 25037218
[TBL] [Abstract][Full Text] [Related]
59. Reconstituted lipoprotein: a versatile class of biologically-inspired nanostructures.
Bricarello DA; Smilowitz JT; Zivkovic AM; German JB; Parikh AN
ACS Nano; 2011 Jan; 5(1):42-57. PubMed ID: 21182259
[TBL] [Abstract][Full Text] [Related]
60. Apolipoprotein mimetics in cancer.
Delk SC; Chattopadhyay A; Escola-Gil JC; Fogelman AM; Reddy ST
Semin Cancer Biol; 2021 Aug; 73():158-168. PubMed ID: 33188891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
